NCT00712985View on ClinicalTrials.gov

Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

Zometa

Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose

Trial Locations (1)

17033

Penn State Milton S. Hershey Medical Center, Hershey

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Milton S. Hershey Medical Center

OTHER

NCT00712985 - Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL) | Biotech Hunter | Biotech Hunter